ADH-1 (trifluoroacetate)

ADH-1 trifluoroacetate is an N-cadherin antagonist, which inhibits N-cadherin mediated cell adhesion.

Product Specifications

CAS Number

[1135237-88-5]

UNSPSC

12352209

Target

Cadherin

Type

Peptides

Related Pathways

Cytoskeleton

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Exherin-trifluoroacetate.html

Purity

99.74

Solubility

DMSO : ≥ 43 mg/mL|H2O : 33.33 mg/mL (ultrasonic)

Smiles

O=C([C@@H](NC([C@H](C(C)C)NC([C@H](C)NC([C@H](CC1=CN=CN1)N2)=O)=O)=O)CSSC[C@H](NC(C)=O)C2=O)N.O=C(O)C(F)(F)F

Molecular Formula

C24H35F3N8O8S2

Molecular Weight

684.71

References & Citations

[1]Shintani Y, et al. ADH-1 suppresses N-cadherin-dependent pancreatic cancer progression. Int J Cancer. 2008 Jan 1;122 (1) :71-7.|[2]Li H, et al. ADH1, an N-cadherin inhibitor, evaluated in preclinical models of angiogenesis and androgen-independent prostate cancer. Anticancer Drugs. 2007 Jun;18 (5) :563-8.|[3]Turley RS, et al. Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. Ann Surg. 2015 Feb;261 (2) :368-77